New drug combo aims to tackle Hard-to-Treat myeloma
NCT ID NCT06645678
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, mezigdomide and elranatamab, in 75 people with relapsed or refractory multiple myeloma (a blood cancer that has come back or stopped responding to treatment). The goal is to see how well the combination works and how safe it is. Participants will receive injections of elranatamab along with oral mezigdomide, with doses adjusted based on response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mezigdomide and elranatamab
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial (Phase I/II) with only 75 participants, so results may not apply broadly. Side effects from the drugs could be significant, and the combination may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center, University of Ulsan College of Medicine
RECRUITINGSeoul, South Korea
-
Chonnam National University Hwasun Hospital
RECRUITINGHwasun, South Korea
-
National University Hospital (NUH)
RECRUITINGSingapore, Singapore
-
Samsung Medical Center, Sungkyunkwan University School of Medicine
RECRUITINGSeoul, South Korea
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
-
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea
RECRUITINGSeoul, South Korea
-
Singhealth Duke NUS blood cancer center
RECRUITINGSingapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough myeloma: early trial of BP2202 begins
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
- New drug combo aims to tackle Hard-to-Treat myeloma
- New hope for myeloma patients: epunamin combo under study
- New combo therapy aims to tackle Hard-to-Treat myeloma
- New drug duo aims to tackle Hard-to-Treat myeloma